Stay updated with breaking news from Roberto Iacone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BASEL, Switzerland, April 29, 2024--Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately. Alberto joined Alentis in 2021 as Head of Oncology.
Velji brings more than 20 years of experience in biotech financial servicesBASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointe...
Alentis Therapeutics has received fast track designation from the FDA for ALE.C04 to treat patients with head and neck squamous cell carcinoma.
The FDA has granted fast track designation to ALE.C04 for use as a potential therapeutic option in patients with recurrent or metastatic, Claudin-1–positive head and neck squamous cell carcinomas.
The trial confirms ALE.F02's good safety profile, exposure and target biological activity Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing breakthrough treatments